Holen Sie sich die Stockscreener-App
1.625
3.85%
-0.065
Schlusskurs vom Vortag:
$1.69
Offen:
$1.69
24-Stunden-Volumen:
837.71K
Relative Volume:
0.41
Marktkapitalisierung:
$242.89M
Einnahmen:
$42.17M
Nettoeinkommen (Verlust:
$-183.12M
KGV:
-1.1159
EPS:
-1.4562
Netto-Cashflow:
$-138.51M
1W Leistung:
-10.71%
1M Leistung:
+0.93%
6M Leistung:
+25.97%
1J Leistung:
+82.46%
1-Tages-Spanne:
$1.61
$1.76
1-Wochen-Bereich:
$1.61
$2.0598
52-Wochen-Spanne:
$0.71
$2.6158
Coherus Oncology Inc Stock (CHRS) Company Profile
Firmenname
Coherus Oncology Inc
Sektor
Branche
Telefon
(650) 649-3530
Adresse
C/O DENNIS M. LANFEAR, REDWOOD CITY, CA
Compare CHRS vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CHRS
Coherus Oncology Inc
|
1.625 | 252.61M | 42.17M | -183.12M | -138.51M | -1.4562 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.01 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
746.43 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
705.43 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.58 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.48 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Coherus Oncology Inc Stock (CHRS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-23 | Eingeleitet | Oppenheimer | Outperform |
| 2025-09-04 | Hochstufung | Maxim Group | Hold → Buy |
| 2024-08-16 | Herabstufung | UBS | Buy → Neutral |
| 2023-11-17 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-11-08 | Herabstufung | Maxim Group | Buy → Hold |
| 2023-07-24 | Eingeleitet | Citigroup | Buy |
| 2023-05-01 | Eingeleitet | Truist | Buy |
| 2023-03-28 | Hochstufung | UBS | Neutral → Buy |
| 2022-06-14 | Eingeleitet | UBS | Neutral |
| 2022-03-07 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-07-16 | Eingeleitet | BofA Securities | Neutral |
| 2020-04-17 | Eingeleitet | SunTrust | Buy |
| 2019-08-13 | Eingeleitet | Mizuho | Buy |
| 2019-08-02 | Bestätigt | H.C. Wainwright | Buy |
| 2019-08-02 | Bestätigt | Maxim Group | Buy |
| 2019-06-11 | Eingeleitet | Barclays | Overweight |
| 2019-05-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-08-28 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-03-09 | Bestätigt | Maxim Group | Buy |
| 2017-08-08 | Bestätigt | JP Morgan | Overweight |
| 2017-06-13 | Bestätigt | Maxim Group | Buy |
| 2017-05-05 | Eingeleitet | BMO Capital Markets | Outperform |
| 2016-10-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2016-09-07 | Eingeleitet | Maxim Group | Buy |
| 2016-07-27 | Eingeleitet | Citigroup | Buy |
| 2016-01-20 | Eingeleitet | Credit Suisse | Outperform |
Alle ansehen
Coherus Oncology Inc Aktie (CHRS) Neueste Nachrichten
Coherus Oncology (CHRS) Revenue Gains Contrast With Persistent US$46 Million Quarterly Losses - Sahm
Coherus outlines $175M annualized LOQTORZI target by 2028 as commercial expansion accelerates - MSN
Coherus BioSciences at The Citizens Conference: Strategic Oncology Shift By Investing.com - Investing.com Canada
Coherus Oncology Doubles LOQTORZI Revenue in 2025, Advances Oncology Pipeline and Significantly Reduces Debt 1 - Minichart
Oppenheimer reiterates Coherus Biosciences stock rating at Outperform By Investing.com - Investing.com South Africa
Oppenheimer reiterates Coherus Biosciences stock rating at Outperform - Investing.com
Coherus Oncology, Inc. 2025 Annual Report – LOQTORZI Sales Growth, Pipeline Advances, and Strategic Shift to Immuno-Oncology - Minichart
Coherus Oncology Inc (CHRS) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada
Coherus Oncology Q4 2025 Earnings Call Transcript - MarketBeat
Coherus Oncology Inc (CHRS) Q4 2025 Earnings Call Highlights: St - GuruFocus
Coherus Oncology (CHRS) Sees Strong Growth with LOQTORZI - GuruFocus
Coherus Oncology Q4 Earnings Call Highlights - MarketBeat
CHRS Q4 Revenue Falls Short but Strategic Shift Shows Promise - GuruFocus
Coherus Oncology (CHRS) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Coherus Oncology Q4 2025 Results: Quarterly Loss, Annual ProfitNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
Coherus Oncology: Fourth Quarter Financial Results Overview - Bitget
Coherus Oncology (NASDAQ:CHRS) Announces Quarterly Earnings Results, Misses Estimates By $0.03 EPS - MarketBeat
Coherus Oncology: Q4 Earnings Snapshot - Barchart.com
Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update - The Manila Times
Coherus BioSciences (CHRS) Q4 Earnings Preview: What to Expect - GuruFocus
Coherus Oncology Touts 90% Debt Cut, LOQTORZI Sales Surge, Sets 2026 Data Catalysts - National Today
Coherus Oncology Inc expected to post a loss of 34 cents a shareEarnings Preview - TradingView
Coherus BioSciences's Earnings Outlook - Benzinga
How The Coherus Oncology (CHRS) Narrative Is Evolving Around Clinical Catalysts And Valuation Risks - Yahoo Finance
Coherus BioSciences at TD Cowen Conference: Strategic Oncology Shift - Investing.com
CHRS: Strong oncology focus, robust pipeline, and accelerating LOQTORZI sales drive future growth - TradingView
CHRS: Rapid oncology transformation, strong LOQTORZI growth, and promising pipeline assets drive outlook - TradingView
Coherus Oncology, Inc. to Release 2025 Financial Results on March 9, 2026, with Conference Call to Follow - Quiver Quantitative
Coherus Oncology to Report Full Year and Fourth Quarter 2025 Financial Results on March 9, 2026 - GlobeNewswire
Coherus Oncology (CHRS) Projected to Post Quarterly Earnings on Monday - MarketBeat
CHRS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Phathom Pharmaceuticals, Inc. (PHAT) Posts Fourth Quarter Loss, Surpasses Revenue Projections - Bitget
Hepatocellular Carcinoma Clinical Trial Pipeline Shows Potential with Active Contributions from 90+ Key Companies | DelveInsight - StreetInsider
Hepatocellular Carcinoma Clinical Trial Pipeline Shows - openPR.com
Coherus Oncology (NASDAQ:CHRS) Stock Passes Above 200-Day Moving AverageWhat's Next? - MarketBeat
Coherus Oncology to Participate in Upcoming Investor Conferences - GlobeNewswire
Coherus: Downgrade To 'Hold' On Potential Advancement Of Anti-CCR8 CHS-114 (NASDAQ:CHRS) - Seeking Alpha
Coherus Oncology announces proposed public offering of common stock - MSN
How Recent Developments Are Rewriting The Story For Coherus Oncology (CHRS) - Yahoo Finance
Coherus closes $50.1 million public offering of common stock - Investing.com Australia
Coherus Biosciences Completes $47 Million Equity Offering - TipRanks
Coherus closes $50.1 million public offering of common stock By Investing.com - Investing.com UK
Coherus Oncology, Inc. Announces Closing of Public Offering of Common Stock - The Manila Times
Oncology biotech Coherus raises $50M for LOQTORZI and clinical programs - Stock Titan
Coherus Oncology (NASDAQ: CHRS) raises $47M through common stock offering - Stock Titan
More drugmakers are turning to cancer combos. Will it help patients live longer? - PharmaVoice
Coherus Oncology, Inc. (NASDAQ:CHRS) Given Average Rating of "Hold" by Analysts - MarketBeat
Coherus Oncology prices $50.1 million public offering of common stock By Investing.com - Investing.com Canada
Coherus BioSciences stock falls after pricing $50.1 million share offering By Investing.com - Investing.com Australia
CHRS Should I Buy - Intellectia AI
CHRS Successfully Completes Joint Book-Running Offering - GuruFocus
Finanzdaten der Coherus Oncology Inc-Aktie (CHRS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):